What is the hepatitis B vaccination regimen in chronic kidney disease?

2018 ◽  
Vol 85 (1) ◽  
pp. 32-34 ◽  
Author(s):  
Kheng Yong Ong ◽  
Hong Yun Wong ◽  
Giat Yeng Khee
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Hepatitis B Vaccination ◽  
Vaccination Regimen

scholarly journals Levamisole as an adjuvant to hepatitis B vaccination in patients with chronic kidney disease

2015 ◽  
Vol 3 (2) ◽  
pp. 87-93
Author(s):  
Mohammad-Hossein Somi ◽  
Mohammad-Reza Ardalan ◽  
Majid Moghadaszadeh ◽  
Masoud Shirmohamadi ◽  
Reza Piri ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Hepatitis B Vaccination

scholarly journals Seroprotection after hepatitis B vaccination in chronic kidney disease patients with modified schedule and dosage

2010 ◽  
Vol 4 (06) ◽  
pp. 389-392 ◽  
Author(s):  
Shireen Siddiqui ◽  
Abida Malik ◽  
Indu Shukla ◽  
Meher Rizvi ◽  
Shahzad F. Haque
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Cost Effective ◽  
Hepatitis B Vaccination ◽  
Healthy Population ◽  
Patient Response ◽  
Vaccine Schedule ◽  
Antibody Titers

Background: This study was conducted to determine the efficacy of four doses of 40 µg vaccine in chronic kidney disease patients as compared to the three-dose 20 µg vaccine schedule given to the normal healthy population. Methodology: This study included 130 chronic kidney disease patients. Of these 84 were given 20 µg vaccine (52 patients were given three doses at 0, one and two months, and 32 patients were given four doses at 0, one, two and six months) and 46 patients were given 40 µg vaccine (30 patients were given three doses at 0, one and two months and 16 patients were given four doses at 0, one, two and six months). Patient response was assessed by measuring antibodies to hepatitis B surface antigen (anti HBs) one month after receiving the third and fourth doses each. Results: Of the patient who received three doses of 20 µg vaccine, 57.7% showed seroprotection while 68.7% of the patients who received four doses of this vaccine showed seroprotection. In contrast, 60% of the patients who received three doses of 40 µg vaccine had seroprotective antibody titers while 87.5% of the patients receiving four doses of 40 µg vaccine showed seroprotection. Conclusions: Seroprotection after four doses of 40 µg vaccine at 0, one, two, and six months was found to be better and cost effective in chronic kidney disease patients compared to three doses of 20 µg vaccine given to normal healthy individuals with adequate renal function.

Variables linked to hepatitis B vaccination success in non-dialyzed chronic kidney disease patients: Use of a bayesian model

2019 ◽  
Vol 15 (4) ◽  
pp. 215-219
Author(s):  
Yves Dimitrov ◽  
Michel Ducher ◽  
Marc Kribs ◽  
Guillaume Laurent ◽  
Sarah Richter ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Bayesian Model ◽  
Hepatitis B Vaccination

scholarly journals Hepatitis B Vaccination in Advanced Chronic Kidney Disease: A Quality Improvement Project at a Veteran Affairs Chronic Kidney Disease Clinic

2021 ◽  
Vol 13 (4) ◽  
pp. 1036-1042
Author(s):  
Jacob Hettenbaugh ◽  
Ryan Mullane ◽  
Gayle Gillispie ◽  
Valerie Shostrom ◽  
Linda Flores ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Quality Improvement ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Seroconversion Rate ◽  
Vaccination Schedule ◽  
Hepatitis B Vaccination ◽  
Improvement Program ◽  
Improvement Project ◽  
Ckd Stage

Hepatitis B vaccination is recommended in all patients with end-stage kidney disease (ESKD). However, only 50–60% of these patients achieve protective antibody levels if immunized after starting dialysis. Strategies to overcome this low seroconversion rate include a 6-month vaccination schedule starting earlier [chronic kidney disease (CKD) stage 4 and 5] to ensure immunity when patients progress to ESKD. We conducted a quality improvement program to immunize pre-dialysis patients. Patients who were found to have a negative baseline serology with a negative hepatitis B surface antibody level (HBsAb) were offered vaccination on a 6-month schedule (0, 1 and 6 months) with one of two available vaccines within the VA system (Recombivax™ or Engerix™). HBsAb titers were checked 3–4 months later, and titers ≥ 12 mIU/mL were indicative of immunity at VA. Patients who did not seroconvert were offered a repeat schedule of three more doses. We screened 198 patients (187 males and 11 females) with CKD 4 and 5 [glomerular filtration rate (GFR) < 29 mL/min/1.73 m2]. The median age of this cohort was 72 years (range 38–92 years). During the study period of 5 years (2015–2020), 10 patients were excluded since their GFR had improved to more than 30 mL/min/1.73 m2, 24 others had baseline immunity and 2 refused vaccination. The hepatitis B vaccination series was not started on 106 patients. Of the remaining 56, 12 patients progressed to ESKD and started dialysis before completion of the vaccination schedule, 6 expired and 1 did not come to clinic in 2020 due to the pandemic. Of the 37 patients who completed the vaccination schedule, 16 achieved seroconversion with adequate HBsAb titers, 10 did not develop immunity despite a second hepatitis B vaccination series, while 11 did not get a second series. Given the low seroconversion rate, albeit in a small cohort, vaccination should be considered in patients with earlier stages of CKD. Other options include studies on FDA approved vaccines of shorter duration. We plan to increase awareness among nephrologists, patients and nursing staff about the importance of achieving immunity against hepatitis B.

Sign in / Sign up

Export Citation Format

Share Document